🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Co-Diagnostics, Inc. (CODX)
NASDAQ: CODX · Real-Time Price · USD
0.1977
+0.0017 (0.87%)
At close: Nov 18, 2026, 4:00 PM EST
0.1975
-0.0002 (-0.10%)
After-hours: Nov 18, 2026, 4:14 PM EST

Co-Diagnostics Statistics

Total Valuation

Co-Diagnostics has a market cap or net worth of $2.08 million. The enterprise value is $2.93 million.

Market Cap2.08M
Enterprise Value 2.93M

Important Dates

The last earnings date was Tuesday, November 10, 2026, before market open.

Earnings Date Nov 10, 2026
Ex-Dividend Date n/a

Share Statistics

Co-Diagnostics has 10.51 million shares outstanding. The number of shares has increased by 230.57% in one year.

Current Share Class 10.51M
Shares Outstanding 10.51M
Shares Change (YoY) +230.57%
Shares Change (QoQ) +45.54%
Owned by Insiders (%) 1.29%
Owned by Institutions (%) 3.36%
Float 7.81M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 2.39
Forward PS 11.87
PB Ratio 0.15
P/TBV Ratio 0.93
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.38
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.77, with a Debt / Equity ratio of 0.17.

Current Ratio 0.77
Quick Ratio 0.31
Debt / Equity 0.17
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -192.78% and return on invested capital (ROIC) is -277.60%.

Return on Equity (ROE) -192.78%
Return on Assets (ROA) -63.74%
Return on Invested Capital (ROIC) -277.60%
Return on Capital Employed (ROCE) -285.39%
Weighted Average Cost of Capital (WACC) 12.40%
Revenue Per Employee $7,469
Profits Per Employee -$412,834
Employee Count115
Asset Turnover 0.03
Inventory Turnover 0.78

Taxes

Income Tax -453,528
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -97.86% in the last 52 weeks. The beta is 3.20, so Co-Diagnostics's price volatility has been higher than the market average.

Beta (5Y) 3.20
52-Week Price Change -97.86%
50-Day Moving Average 0.74
200-Day Moving Average 2.04
Relative Strength Index (RSI) 21.72
Average Volume (20 Days) 5,676,564

Short Selling Information

The latest short interest is 981,329, so 9.34% of the outstanding shares have been sold short.

Short Interest 981,329
Short Previous Month 656,373
Short % of Shares Out 9.34%
Short % of Float 12.56%
Short Ratio (days to cover) 2.21

Income Statement

In the last 12 months, Co-Diagnostics had revenue of $858,888 and -$47.48 million in losses. Loss per share was -$12.86.

Revenue858,888
Gross Profit 174,077
Operating Income -29.34M
Pretax Income -47.93M
Net Income -47.48M
EBITDA -28.39M
EBIT -29.34M
Loss Per Share -$12.86
Full Income Statement

Balance Sheet

The company has $714,803 in cash and $1.56 million in debt, with a net cash position of -$849,700 or -$0.08 per share.

Cash & Cash Equivalents 714,803
Total Debt 1.56M
Net Cash -849,700
Net Cash Per Share -$0.08
Equity (Book Value) 9.43M
Book Value Per Share 1.29
Working Capital -573,722
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$26.88 million and capital expenditures -$307,268, giving a free cash flow of -$27.19 million.

Operating Cash Flow -26.88M
Capital Expenditures -307,268
Depreciation & Amortization 947,214
Net Borrowing n/a
Free Cash Flow -27.19M
FCF Per Share -$2.59
Full Cash Flow Statement

Margins

Gross Margin 20.27%
Operating Margin -3,415.85%
Pretax Margin -5,580.41%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Co-Diagnostics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -230.57%
Shareholder Yield -230.57%
Earnings Yield -6,506.14%
FCF Yield -1,323.70%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (3Y) 357.25%
EPS Growth Forecast (3Y) n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.

Last Split Date Jan 2, 2026
Split Type Reverse
Split Ratio 1:30

Scores

Co-Diagnostics has an Altman Z-Score of -16.62 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -16.62
Piotroski F-Score 2